Navigation Links
Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594
Date:5/19/2008

ve tissue of the joints and in the kidneys, leading to inflammation, the formation of disfiguring nodules (tophi), intermittent attacks of severe pain (acute flares), and kidney damage (nephropathy). While gout is a treatable condition, there are limited treatment options, and a number of adverse effects are associated with current therapies. No new therapies have been approved by the FDA for the treatment of hyperuricemia associated with gout in the past 40 years.

About RDEA594

RDEA594 is a development candidate that has potential for treating gout patients with hyperuricemia. RDEA594 is a metabolite of RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI) in development for the treatment of HIV. In Phase 1 studies with RDEA806 in healthy volunteers, increased urinary excretion of uric acid was observed in the first 24 hours after dosing, with statistically significant, exposure-dependent, decreases in serum uric acid of 35% to 50% observed following 10-14 days of dosing. RDEA594 exhibits a concentration-dependent inhibitory effect on the URAT1-mediated uptake of uric acid ex vivo and is believed to be the active moiety responsible for the uric acid-lowering effects of RDEA806. Approximately 90% of hyperuricemic patients are considered to be under-excretors of uric acid, so increasing excretion may provide the most physiologically appropriate treatment. RDEA594 does not have significant antiviral activity.

About Ardea Biosciences

Ardea Biosciences, Inc., of San Diego, California, is a biotechnology company focused on the discovery and development of small-molecule therapeutics for the treatment of HIV, cancer and inflammatory diseases, including gout. We have four drug candidates in clinical trials and others in preclinical development and discovery. Our most advanced development candidate is RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI), which is in a Phase 2a study for the treatment of HIV. We have evalu
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
2. Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors
3. Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load
4. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
5. Ardea Biosciences, Inc. Announces New Clinical Development Program Directed Toward the Treatment of Gout
6. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
7. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
8. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
9. Catalyst Biosciences Selects Drug Development Candidate in Factor VIIa Program for Hemophilia
10. Neurocrine Biosciences Reports First Quarter 2008 Results
11. Sangamo BioSciences Announces Presentation of Data on ZFP Therapeutic for Glioblastoma at American Association for Cancer Research (AACR) Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... -- Neurelis, Inc. ("Neurelis") today announced an agreement with ... by Biotie to purchase Neurelis, clearing the way for ... for pediatric and adult epilepsy patients who experience acute ... has advanced the development program for NRL-1 and worked ... required for NDA submission to the FDA.  Given the ...
(Date:7/10/2014)... -- Integrated Silicon Solution, Inc. (Nasdaq: ISSI ... solutions, today announced that it will host its earnings ... a.m. Pacific Time (10:00 a.m. Eastern Time) to discuss ... quarter ended June 30, 2014. To access ... a.m. Pacific time on July 24, 2014.  The participant ...
(Date:7/10/2014)... --  Ventana Medical Systems, Inc.  (Ventana), a member of ... an agreement with Merck KGaA, Darmstadt, Germany ... the United States and ... division on the development and commercialization of a companion ... diagnostic assays. In alignment with Merck KGaA,s strategic approach ...
Breaking Medicine Technology:Neurelis Regains Rights to Intranasal Diazepam Program 2Neurelis Regains Rights to Intranasal Diazepam Program 3Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3
... Takeda Pharmaceuticals International, Inc., a wholly-owned subsidiary ... its Pharmaceutical Development Division has entered into strategic ... and Quintiles, two of the world,s largest full-service ... the agreements, Covance and Quintiles will work in ...
... Viral Genetics, Inc. (Pink Sheets: VRAL ) ... and Advisor Mr. Richard Gerstner will receive the Lauren F. ... award presentation is set for the Illusions of Lyme Gala, ... being recognized for her research on Targeted Peptide treatment for ...
Cached Medicine Technology:Takeda Enters Into Global Strategic Partnerships With Covance and Quintiles 2Viral Genetics' Researcher and Advisor Set to Share Award 2Viral Genetics' Researcher and Advisor Set to Share Award 3
(Date:7/13/2014)... Texas (PRWEB) July 13, 2014 Epidemiologists ... aGVHD in the 6MM, from 8,062 diagnosed incident cases ... at an Annual Growth Rate (AGR) of 4.35%, during ... the highest number of diagnosed incident cases of aGVHD ... Spain will have the lowest number of diagnosed incident ...
(Date:7/13/2014)... According to the Kidney Disease Solution book review recently updated ... what to do to eliminate the root cause of ... review that readers can easily learn what foods to avoid ... Vkool also informs in its Kidney Disease Solution review that ... naturally. The book consists of a collection of natural remedies ...
(Date:7/13/2014)... 2014 Celebrity fitness trainer and former ... promotional partnership with Aqua Health Labs for their flagship ... supplement . The collaboration was recently announced live on ... trainer , actor, model, and a two time World ... celebrities, he has prepared stars including Demi Moore, Hilary ...
(Date:7/13/2014)... If Dr. Lawrence Power has his way, the innovative ... http://www.HealthYourself101.com will expand people’s understanding of the causes, consequences, ... out to provide a health education platform on this modern ... say it? – entertaining to dig into and learn from. ... remote learner – the solitary individual signing on from a ...
(Date:7/13/2014)... Recently, iFitDress.com, one of the most popular suppliers of ... a new selection of beautiful evening dresses ... promotion for these evening gowns. Now, everybody can enjoy ... thousands of graceful gowns in its online store. Most ... Italy and many other countries. They are highly appreciated ...
Breaking Medicine News(10 mins):Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 2Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 3Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 4Health News:Kidney Disease Solution Book Review Exposes Duncan Capicchiano's Newly Updated Kidney Disease Treatment Plan – Vkool.com 2Health News:Kidney Disease Solution Book Review Exposes Duncan Capicchiano's Newly Updated Kidney Disease Treatment Plan – Vkool.com 3Health News:Celebrity Fitness Expert Supports Revolutionary New Health Supplement 2Health News:Retired Ann Arbor Physician and Professor Wields New Media to Teach Health Science 2Health News:Retired Ann Arbor Physician and Professor Wields New Media to Teach Health Science 3Health News:Retired Ann Arbor Physician and Professor Wields New Media to Teach Health Science 4Health News:New and Beautiful Evening Dresses Unveiled by iFitDress.com 2
... cause of death in the Intensive Care Unit (ICU) is ... central nervous system// and cardiovascular system. The study also revealed ... who are out of the ICU but still in hospital ... ,This study is published in the journal Critical Care. Investigation ...
... were performed, much has been learned about illegal transplants of ... are quite common in countries like India and China ... Africa, people sell their kidneys to foreigners. ,Much ... news was in Jan 2006, about an Indian who died ...
... feelings either way has been brought up by senior doctors ... mercy killing of// new borns who are severely disabled. ... this recommendation as the solution to the incresing numbers of ... alive because of the advanced technology in the medical ...
... injuries like low back pain and disc disorder now ... gas could bring better results than conventional// surgery. ... started gaining ground in western countries, according to senior ... subject., ,'Ozonucleolysis or ozone discectomy for curing spinal ...
... charged with cheating the organisation he earlier worked for has ... Cell of Delhi Police arrested Alok Tomar, a former editor ... ,Tomar was arrested after he flew into the capital ... Deputy Commissioner of Police Alok Kumar. ,Kumar said ...
... rabies, a farmer's extended family in Bihar has to now ... as they had drunk the milk of the infected cows. ... in Dakhin Tola in Purnea district, were bitten by a ... weeks, according to local media reports here. ,The farmer's ...
Cached Medicine News:Health News:Consider Euthanasia For Severely Disabled Babies, College Tells Doctors 2Health News:Ozone Treatment - A Good Alternative For Spinal Injury 2